With the release of Zyprexa, a second-generation antipsychotic, Eli Lilly was certain it had hit pay dirt. The second-generation antipsychotics, known as the atypical antipsychotics, or atypicals, had an improved side effect profile over the older antipsychotics, and the original research on large numbers of schizophrenics in the 1990s showed great improvement for patients treated with […]
February 28, 2012 by candidaabrahamson
6